New York State Common Retirement Fund Makes New Investment in Heartflow, Inc. $HTFL

New York State Common Retirement Fund bought a new stake in Heartflow, Inc. (NASDAQ:HTFL) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 119,289 shares of the company’s stock, valued at approximately $4,015,000. New York State Common Retirement Fund owned approximately 0.14% of Heartflow at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Baillie Gifford & Co. acquired a new position in shares of Heartflow during the 3rd quarter worth about $101,182,000. Emerald Mutual Fund Advisers Trust acquired a new position in Heartflow during the third quarter worth approximately $4,418,000. TrueMark Investments LLC bought a new stake in Heartflow in the third quarter valued at approximately $918,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Heartflow in the third quarter valued at approximately $234,000. Finally, TFC Financial Management Inc. bought a new position in shares of Heartflow during the 3rd quarter worth approximately $40,000.

Heartflow Stock Up 6.7%

NASDAQ HTFL opened at $27.74 on Friday. The firm has a 50-day simple moving average of $30.33. Heartflow, Inc. has a 12-month low of $25.38 and a 12-month high of $41.22. The company has a market cap of $2.36 billion and a P/E ratio of -15.33.

Insider Activity at Heartflow

In other news, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of the company’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $28.05, for a total transaction of $56,100,000.00. Following the completion of the sale, the insider directly owned 10,448,158 shares in the company, valued at approximately $293,070,831.90. This represents a 16.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey C. Lightcap purchased 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was bought at an average price of $26.34 per share, for a total transaction of $1,053,600.00. Following the transaction, the director directly owned 40,000 shares of the company’s stock, valued at $1,053,600. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Analyst Ratings Changes

HTFL has been the subject of several research reports. Canaccord Genuity Group raised their price target on Heartflow from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Weiss Ratings restated a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. JPMorgan Chase & Co. upped their price target on shares of Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Wells Fargo & Company started coverage on shares of Heartflow in a research report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price objective for the company. Finally, Stifel Nicolaus upped their target price on Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $38.50.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.